Humira
$ 755,00 – $ 3 737,00Price range: $ 755,00 through $ 3 737,00
Manjishtha
$ 15,00 – $ 30,00Price range: $ 15,00 through $ 30,00
Lyrica
$ 50,00 – $ 540,00Price range: $ 50,00 through $ 540,00
Lyrica is a highly effective medication primarily used to manage neuropathic pain associated with diabetic peripheral neuropathy and spinal cord injury. It is also widely recognized for its ability to provide significant relief for individuals suffering from the chronic, widespread discomfort caused by fibromyalgia. Additionally, this treatment is specifically indicated to alleviate postherpetic neuralgia, which is the persistent nerve pain that can follow a shingles outbreak. For those with epilepsy, Lyrica serves as a reliable adjunctive therapy for managing partial-onset seizures in adult patients. By calming overactive nerves, the medication helps stabilize electrical activity in the nervous system to improve overall daily comfort.
Active substance: Pregabalin
SKU:
Lyrica
Categories: AntiConvulsants, AntiDepressants
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM
Each dosage option has its own packaging choices.
Description
Lyrica belongs to a class of medications known as anticonvulsants or neuropathic pain agents, specifically functioning as an alpha-2-delta ligand. It is an FDA-approved prescription medication indicated for the management of specific neuropathic pain conditions, fibromyalgia, and as adjunctive therapy for partial-onset seizures in select patient populations. Because pregabalin affects chemical signaling within the central nervous system, treatment requires ongoing medical oversight and individualized dosage adjustment.
As a regulated prescription drug classified under federal controlled substance schedules, Lyrica must be dispensed and used strictly in accordance with federal and state regulations. Patients receiving this medication should follow their prescribing clinician’s explicit guidance to ensure both therapeutic efficacy and safety during treatment.
| Attribute | Details |
|---|---|
| Drug name | Lyrica |
| Active ingredient (INN) | Pregabalin |
| Therapeutic class | Anticonvulsant / GABA Analog |
| Dosage form | Oral capsules, Oral solution |
| Route of administration | Oral |
| Primary purpose | Neuropathic pain, Fibromyalgia, Seizure control |
| Prescription status | Prescription only (Rx) |
How the drug works
The active constituent of Lyrica, pregabalin, is a structural analog of gamma-aminobutyric acid (GABA), yet it does not bind directly to GABA-A, GABA-B, or benzodiazepine receptors. Instead, the drug binds with high affinity to the alpha-2-delta auxiliary subunit site of voltage-gated calcium channels in central nervous system tissues. By binding to this site, pregabalin reduces calcium influx into hyperexcited neurons.
Consequently, this mechanism leads to a decrease in the presynaptic release of several excitatory neurotransmitters, including glutamate, norepinephrine, and substance P. Through this selective inhibition of central neuronal hyper-excitability, the medication provides analgesic and anticonvulsant effects across target regions of the nervous system.
Main uses
Lyrica holds official FDA approval for several specific neurological and pain indications. Authorized uses include the treatment of neuropathic pain associated with diabetic peripheral neuropathy, management of postherpetic neuralgia following shingles, and management of fibromyalgia. Additionally, it is indicated as an adjunctive treatment for adult and pediatric patients 1 month of age and older with partial-onset seizures, as well as for neuropathic pain associated with spinal cord injury.
In clinical practice, healthcare providers may occasionally evaluate off-label applications for this drug. For example, the treatment of generalized anxiety disorder (GAD) or specific psychiatric symptoms represents an off-label use in the United States, despite holding approval in other international jurisdictions. Any off-label application must be explicitly directed and monitored by a qualified physician.
Dosing schedule
The dosing regimen for Lyrica is determined by the patient’s medical condition, clinical response, and kidney function parameters. Initial dosing for conditions like diabetic neuropathy often starts at lower daily quantities (such as 50 mg taken three times daily or 75 mg taken twice daily) and may be gradually increased by the prescriber up to maximum recommended therapeutic limits.
Oral capsules and liquid solutions are taken with or without food and should be consumed at regular intervals. Patients undergoing dosage changes require close clinical observation. Abrupt discontinuation of therapy should be avoided; when stopping treatment, healthcare providers reduce the daily dose gradually over a minimum of one week to minimize withdrawal symptoms or rebound seizure activity.
How it’s absorbed and eliminated
Following oral administration under fasting conditions, pregabalin is rapidly absorbed, reaching peak plasma concentrations within 1.5 hours. The oral bioavailability of the drug is high, estimated at approximately 90% or greater, and is independent of the administered dose. Taking the medication with food decreases the peak concentration rate slightly, but total drug absorption remains clinically unchanged.
Pregabalin undergoes negligible hepatic metabolism in humans, with approximately 98% of the absorbed dose excreted unchanged in the urine. The mean elimination half-life is approximately 6 hours in individuals with normal renal function. Because renal excretion is the primary clearance pathway, dosage adjustments are required for patients with reduced kidney function or those undergoing hemodialysis.
Signs of improvement
Evaluating the therapeutic effect of Lyrica depends on the specific medical condition being treated. For patients with neuropathic pain or fibromyalgia, signs of clinical improvement often manifest as a gradual reduction in burning, sharp, or shooting sensations, along with improvements in pain-related sleep disruption. Initial relief may be reported within the first week of therapy, though maximal benefit usually develops over several weeks of consistent administration.
In individuals taking the medication for partial-onset seizures, effectiveness is evaluated by a sustained reduction in seizure frequency and severity. Patients should maintain a symptom diary to assist their healthcare provider in objectively assessing response.
Adverse reactions
Like all active pharmaceuticals, Lyrica can produce side effects, although not every patient experiences them. The most frequently observed adverse reactions include somnolence (drowsiness), dizziness, dry mouth, peripheral edema (fluid retention in the hands or feet), weight gain, and blurred vision. Dizziness and sleepiness are especially prominent during initial dose titration and may impair physical performance.
Less common but clinically relevant adverse events include ataxia (coordination difficulties), confusion, tremors, euphoric mood, and gastrointestinal disturbances. If mild side effects persist or become troublesome, patients should consult their healthcare provider rather than altering doses independently.
Compatibility with other medicines
Combining Lyrica with central nervous system (CNS) depressants requires heightened caution due to potential additive pharmacological effects. Co-administration with prescription opioids, benzodiazepines, or sedative medications markedly increases the risk of severe sedation, respiratory depression, and profound cognitive impairment. Patients taking central depressants concurrently require close medical supervision.
Additionally, combining this agent with oral antidiabetic drugs of the thiazolidinedione class may increase the frequency of weight gain and peripheral edema. Because pregabalin is excreted unchanged renally, standard metabolic interactions involving cytochrome P450 enzymes are unlikely to alter its pharmacokinetic behavior.
What to avoid while taking it
Patients undergoing treatment with Lyrica should avoid consuming alcohol, as alcohol accentuates central nervous system depression, leading to severe dizziness, drowsiness, and motor impairment. Activities demanding high mental alertness–such as driving or operating complex machinery–must be avoided until the patient understands how the medication affects their coordination and alertness.
Food consumption does not cause dangerous interactions; however, maintaining a consistent daily schedule regarding administration times supports stable blood concentrations over the course of treatment.
Important precautions
Before beginning therapy, patients must inform their prescriber regarding any history of kidney disease, heart failure, substance abuse disorder, or allergic reactions to pregabalin. Antiepileptic drugs, including pregabalin, carry warnings regarding an increased risk of suicidal thoughts or behaviors; patients and caregivers must monitor closely for emerging depression, unusual mood shifts, or self-harm ideation.
Special populations
In pediatric populations, approval is restricted strictly to adjunctive therapy for partial-onset seizures in patients 1 month of age and older. Elderly patients frequently exhibit age-related declines in renal function, necessitating careful renal clearance assessment prior to determining dosage levels. During pregnancy, use should occur only if the potential benefit justifies potential risks to the fetus, and nursing mothers should consult a clinician because pregabalin is excreted into human breast milk.
If you skip a dose
If a dose of Lyrica is missed, it should be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped entirely, resuming the standard administration schedule. Patients must never take two doses simultaneously or increase a single dose to compensate for a missed administration.
Storage and expiration
Lyrica capsules and oral solution should be stored at controlled room temperature, ideally between 68°F and 77°F (20°C to 25°C), with temporary excursions permitted between 59°F and 86°F (15°C to 30°C). Keep the bottle or blister pack tightly closed and protected from excessive heat and moisture. Store securely out of sight and reach of children. Do not use the medication beyond the expiration date stated on the container.
Common questions
Is Lyrica classified as a controlled substance?
Yes, pregabalin is classified as a controlled substance under federal law due to potential risks of physical dependence or misuse, particularly in individuals with a history of substance abuse. Abruptly stopping the medication after prolonged use can trigger withdrawal symptoms such as insomnia, headache, nausea, and anxiety. Tapering under medical supervision helps prevent these effects.
How long does it take to experience pain relief?
Some patients notice an improvement in nerve pain or fibromyalgia symptoms within the first week of initiating therapy. However, achieving maximum therapeutic benefits typically takes several weeks as the daily dosage is gradually adjusted to an effective maintenance level by your physician.
Can I drive while taking this drug?
Because dizziness and somnolence are common adverse effects, driving or operating hazardous equipment is not advised during initial dose titration or following dose increases. You should only resume such activities after determining how the drug impacts your alertness and physical coordination.
What happens if I stop taking the medication abruptly?
Discontinuing treatment suddenly can lead to significant withdrawal symptoms, including rapid heart rate, severe headaches, sweating, diarrhea, and insomnia. For patients taking the medication for seizure control, abrupt cessation may increase seizure frequency. Discontinuation must always follow a physician-guided reduction plan.
Does this medication interact with standard over-the-counter pain relievers?
Over-the-counter pain relievers such as acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen do not typically interact directly with pregabalin. However, combining it with prescription opioid pain medications significantly increases the risk of severe sedation and respiratory depression, requiring strict medical oversight.
This text is for informational purposes only and does not constitute individual medical advice. In accordance with FDA requirements.
Additional information
| Dosage |
75 mg ,150 mg ,300mg |
|---|---|
| Package |
30 caps ,30 pills ,60 caps ,60 pills ,90 caps ,90 pills ,120 caps ,120 pills ,180 pills ,270 caps ,270 pills |
| Ενεργός Ουσία |
Related products
Amitriptyline
$ 41,00 – $ 114,00Price range: $ 41,00 through $ 114,00
Active substance: amitriptyline
More Details
This product has multiple variants. The options may be chosen on the product page
Anafranil
$ 41,00 – $ 457,00Price range: $ 41,00 through $ 457,00
Active substance: Clomipramine
More Details
This product has multiple variants. The options may be chosen on the product page
Daxid
$ 42,00 – $ 229,00Price range: $ 42,00 through $ 229,00
Active substance: Sertraline
More Details
This product has multiple variants. The options may be chosen on the product page
Desyrel
$ 41,00 – $ 206,00Price range: $ 41,00 through $ 206,00
Active substance: Trazodone
More Details
This product has multiple variants. The options may be chosen on the product page
Emsam
$ 66,00 – $ 345,00Price range: $ 66,00 through $ 345,00
Active substance: Selegiline
More Details
This product has multiple variants. The options may be chosen on the product page
Lexapro
$ 40,00 – $ 265,00Price range: $ 40,00 through $ 265,00
Active substance: Escitalopram
More Details
This product has multiple variants. The options may be chosen on the product page
Lithium
$ 16,00 – $ 139,00Price range: $ 16,00 through $ 139,00
Active substance: Lithium
More Details
This product has multiple variants. The options may be chosen on the product page
Paxil
$ 34,00 – $ 445,00Price range: $ 34,00 through $ 445,00
Active substance: paroxetine
More Details
This product has multiple variants. The options may be chosen on the product page
